FDA regulatory actions regarding Novo Nordisk site result in CRL for Incyte
The agency issued a Complete Response Letter for Incyte’s supplemental Biologics License Application, citing inspection findings at Novo Nordisk’s fill-finish facility.
Read the full article on the original site.
Read Full Article